Immunological events in chronic spontaneous urticaria by unknown
Ferrer  Clin Transl Allergy  (2015) 5:30 
DOI 10.1186/s13601-015-0074-7
REVIEW




Chronic spontaneous urticaria (CSU) is a highly debilitating skin disease associated with systemic features. We have 
made significant progress in several aspects relating to this condition. However, the exact physiopathology remains 
unknown. There is mounting evidence for an autoimmune basis, demonstrated by the CSU serum ability to activate 
healthy donors skin mast cells and blood basophils. However, it is only seen among 35–40% of patients. Mast cells and 
basophils play an important role in this skin condition. Both cells in CSU patients have unique features that differenti-
ate them from basophils and mast cells from healthy donors. In the case of basophils, basopenia is typically found in 
CSU patients. Basophils from CSU patients also tend to be hyporesponsive to stimuli that act through the IgE receptor, 
responsive to other stimuli as MCP-1 or C5a, and hyperesponsive when incubated with sera. Eosinophils are also pre-
sent in CSU skin biopsies, yet their exact role has not yet been defined. Likewise, endothelial cells also play a function, 
as indirectly demonstrated by an increase of vasoactive peptides in skin and plasma of CSU patients’ samples. All these 
facts orchestrate a systemic inflammation response producing a significant increase of several inflammatory markers. 
Unfortunately, we lack a unitary model that could explain the exact role of each of these players. In this review, we will 
describe the history and discover the pathway to the present knowledge on the immunological facts of this disease.
© 2015 Ferrer. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Chronic spontaneous urticaria (CSU) consists of the daily 
appearance of pruritic wheals angioedema or both [1] for 
more than 6 weeks. Since the first description recorded 
in history in the 10th century BC in China [2], we have 
greatly improved our clinical approach, severity scoring, 
quality of life assessment, as well as tools to control the 
disease. However, we are still far from understanding the 
physiopathology of the disorder. In this review we will 
briefly narrate the history of the developments that have 
led to a potential explanation of the immunology under-
lying CSU.
Autoimmunity
It was in 1946 when for the first time Malmros [3] con-
ducted for the first time his Autoserum test among 956 
patients with many different types of disease, likened the 
wheal and flare to a histamine reaction, reporting that 
some patients with CSU (6 out of 53 positive) gave a posi-
tive autoserum test. This finding remained overlooked for 
another 47 years until Leznoff [4] noted a 15% prevalence 
of autoimmune thyroid antibodies in patients suffering 
from CSU but with a normal thyroid function. Other 
authors have confirmed these findings [5, 6]. This is the 
reason why thyroid antibody determination can be a use-
ful tool as an indirect marker for autoimmunity.
In 1986, Grattan [7] reported that the serum from 12 
patients suffering from active CSU were able to induce a 
positive autologous skin reaction. Subsequently, Gruber 
and Kaplan [8] demonstrated a non-functional IgG anti-
IgE by an immunoassay. Only one patient with cold urti-
caria showed a functional IgM anti-IgE. Later on, Grattan 
was the first to describe histamine releasing autoantibod-
ies with functional properties of anti-IgE in CSU [9], this 
paper set the scene for the subsequent discoveries. The 
next big step was made when M Greaves and co-work-
ers [10] demonstrated for the first time the functional 
autoantibodies in CSU. CSU sera were indeed able to 
activate basophils from normal donors. This ability was 
increased if the IgE bound to the basophils was removed 
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with lactic acid and decreased when basophils were 
incubated with human IgE that occupies the IgE recep-
tor. These authors also found that in 20% of patients, IgE 
was needed to activate the basophils. In connection with 
this, they deduced that they might have anti IgE anti-
bodies. After [11] they demonstrated mast cell degranu-
lation upon incubation with sera from a group of 163 
CSU patients. Moreover, they also obtained histamine 
release in IgE- and non-IgE-sensitized basophils. They 
detected anti-FcεRI α antibodies in 25% of CSU sera and 
to a lesser extent anti IgE antibodies. Notably, those sera 
that induced basophil histamine release did so with mast 
cells. Fiebiger and coworkers discovered that purified IgG 
from a subset (37%) of CSU patients was able to bind to 
the IgE receptor. They also compared IgG from patients 
with atopic dermatitis and healthy donors and none of 
them demonstrated such an ability [12]. Furthermore 
[13] similar antibodies in other skin autoimmune dis-
eases were also noted but these corresponded to IgG2 or 
IgG4 and were not functional, whereas in the case of CSU 
the antibodies corresponded to IgG1 and IgG3. Interest-
ingly, only IgG1 and IgG3 subtypes are able to activate 
complement.
This hypothesis was confirmed by Kaplan [14] who 
transfected rat leukemia basophils with the α subunit of 
the IgE receptor and confirmed that such activation was 
through the interaction with the IgE receptor. An indirect 
observation of mast cell degranulation upon autologous 
serum injection [15] also confirmed that the antibodies 
against the α subunit of the FcεRI receptor have the abil-
ity to induce mast cell degranulation.
Finaly, Kinet sequenced and cloned the α subunit of 
the IgE receptor and demonstrated [16] through immu-
noblotting that IgG from CSU sera recognized this frac-
tion. This ability was not found in the control sera in any 
instance. They also were able to demonstrate that IgG 
and CSU sera were also able to activate mast cells with 
exactly the same 50% frequency as found in basophils.
Nevertheless, there is no correlation between serum 
reactive IgG antibodies across functional studies, West-
ern-blot analyses and autologous skin tests [17]. The 
reason is still unknown. The cause is multifactorial. The 
high variability in basophil response to patient sera, the 
IgG subclass distribution and the number of α subunits 
occupied as well as conformational or glycosylation dif-
ferences between the cloned and human α subunit are 
the associated factors.
In 2001 Horn [18] using intravenous immuno globu-
lin samples, found Fc-ε α antibodies present in healthy 
donors that cross-react with tetanus toxoid. How-
ever, when Ferrer and co-workers attempted (data not 
published) to inhibit the binding to the α subunit by 
preincubating sera with tetanus toxoid, were not able to 
demonstrate such inhibition. Moreover, these data were 
not further confirmed. Using a tonsilar IgM library this 
group also found [19] antibodies against the α subunit 
of the IgE receptor that were able to induce histamine 
release in healthy donors. However, in order to induce 
such degranulation, removal of the already bound IgE 
was required. The authors hypothesized that these might 
represent conditional antibodies that at some point could 
become pathogenic because those antibodies could bind 
cutaneous mast cells if IgE dissociated from FcεRI due to 
local conditions, thereby eliciting a local wheal. The exist-
ence of such antibodies has not yet been independently 
confirmed.
As was previously mentioned, the IgG1 or IgG3 sub-
types were the subclasses identified in CSU. Utilizing 
purified IgG and decomplemented sera, in a study per-
formed by Ferrer et  al. were able to demonstrate that 
mast cell and basophil histamine release were dose-
dependent on C5a and were inhibited when blocked with 
a C5a antibody receptor [20]. The authors conclude that 
the release of histamine by the antibodies against the α 
subunit of the IgE receptor was increased by C5a activa-
tion [21]. The mechanism on how C5 amplifies mast cell 
activation, as Kaplan points out [22], takes place when 
two IgG molecules bind to two α receptors, thus activat-
ing C5a that consequently activates mast cells. The mech-
anism for generating C5a by immune complex formation 
is more likely to be by two anti-FcεRI IgG molecules 
binding adjacent FceRI on mast cells or basophils. The-
oretically, it could also occur as a consequence of com-
plexes IgG anti-IgE bound to its receptor. This would also 
explain why CSU patients with anti IgE receptor antibod-
ies do not show respiratory nor systemic symptoms.
Furthermore, this ability of CSU serum to activate nor-
mal basophils was demonstrated in different ways such as 
by inducing CD203c [23] or CD63 [24] basophil expres-
sion upon incubation with urticaria sera. Both markers 
are correlated with histamine release. However, not only 
preformed mediators such as histamine were induced, 
but also non-preformed mediators as leukotrienes [24] 
thus indicating that such an ability activates both proxi-
mal and distal signalling pathways. Moreover, Ferrer et al. 
demonstrated that basophil activation also induces the 
production of cytokines such as IL4 [25] which explains 
the inflammatory milieu found in CSU biopsies.
Determinations of the HLA class 2 alleles [26] also 
showed an increase in the HLA DRBI*04 (corrected 
p = 3.6 × 10−6) in patients with positive serum basophil 
histamine releasing activity and autoreactivity or both, 
and a favorable association (which was statistically sig-
nificant) between HLA B*50 [27] and patients with CSU, 
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with an OR (95% CI) of 2.96 (1.17–7.48) consistent with 
an autoimmune basis.
A very interesting review of the evidence supporting 
autoimmunity can be found elsewhere [28].
From an epidemiological point of view, a particu-
larly interesting study was carried out by Confino [29] 
who after following-up a very large CSU population for 
10  years, demonstrated a high association between the 
presence of autoimmune diseases and CSU.
On the basis of all these studies, it is clear that between 
35 and 40% antibodies against the α subunit of the IgE 
receptor and between 5 and 10% react against IgE.
Finally, an indirect evidence in favour of an autoim-
mune mechanism in a subset of CSU patients is the 
beneficial response to immunosuppressive agents and 
immunomodulatory treatment such as cyclosporine [30, 
31], plasmapheresis [32] as well as intravenous gamma 
globulin [33].
Many questions remain open regarding the role of 
autoimmunity which is the most prominent underly-
ing mechanism of the remaining 40–50% of patients in 
whom no autoimmunity is found but whose clinical fea-
tures are identical.
Mast cells
Mast cells along with basophils play a key role in the 
pathophysiology of the disease. The first studies reported 
a significant increase in mast cells in CSU skin lesions 
[34, 35]. However, use of specific anti-tryptase antibod-
ies did not reproduce this finding [36]. Recently, Kay 
[37] reviewed this issue finding as was first reported an 
increase of mast cells in both affected and unaffected 
CSU skin.
As for mast cell functional features, one of the first 
studies found that [38] CSU mast cell responses to skin 
stimuli such as codeine were one hundred times more 
sensitive than normal control skin mast cells. An inter-
esting finding reported by Jacques and co-workers [39] 
pointed out that the levels of histamine measured in 
lesional skin suction blisters correlated with disease 
activity. Likewise, mast cells cultured from peripheral 
CD34+ cells from patients with CSU showed greater 
spontaneous histamine release, increased Syk, and 
decreased SHIP-2 levels as compared with normal 
donors [40]. Ferrer and Schwartz [41] studied tryptase 
levels and found higher tryptase levels in CSU patients as 
compared with healthy controls and atopic donors, and 
also in CSU symptomatic patients at the time of the sam-
ple collection as compared with asymptomatic patients. 
However, when they analysed which type of tryptase was 
elevated, contrary to expectations, this increase was not 
due to mast cell degranulation and did not find a rise in 
mature tryptase levels.
One of the most interesting studies dealing with the 
connection between mast cells and autoimmunity was 
done by Bossi [42] who cultured two mast cell lines, 
one expressing IgE receptor (LAD2) and the other not 
expressing this receptor (HMC-1). Degranulation in both 
mast cell lines following incubation with CSU sera was 
found. Moreover, the supernatants of such cultures were 
able to induce vascular leakage from endothelial cells. 
This fact highlights the importance of endothelial cells 
and explains the increased expression of endothelial cell 
adhesion molecules [43–45]. This issue clearly needs fur-
ther investigation. As Kay [43] recently reported, there is 
an increase in vasoactive peptides in lesional CSU skin 
samples. Kasperska-zajak [46] also found similar data in 
plasma from CSU patients.
Basophils
Although the exact role of basophils in this disease has 
not been demonstrated, it has been shown that periph-
eral blood basophils from CSU patients have unique 
features that reverse upon remission and in response to 
therapy.
A basophil abnormality is of particular interest because 
some patients with chronic urticaria have basopenia. This 
was reported as early as 1962 by Rorsman [47] and con-
firmed later by Grattan [48, 49] who found a correlation 
with urticaria severity, and was again confirmed later by 
Eckman [50, 51]. Interestingly, Rorsman attributed the 
low number of basophils to the presence of an antigen 
antibody reaction that leads to basophil degranulation, 
thus suggesting an autoimmune type of disease. The rea-
son for such basopenia is partially explained because the 
presence of basophils in lesional and non-lesional skin of 
CSU patients and not in normal skin [52–54] has been 
demonstrated.
CSU basophils are different not only in number but 
also in function. In fact, in 1974 Greaves showed that 
basophils of patients with CSU were hyporesponsive to 
anti-IgE, and at that time attributed this feature to in vivo 
desensitization [55]. This quality was later confirmed by 
Kern and Lichtenstein [56] they reported that this feature 
was not observed when stimulation was applied using 
stimuli other than anti-IgE nor was it due to differences 
in histamine content. In a group of 26 patients, Sabroe 
correlated the basophil number, presence of autoanti-
bodies and histamine release upon stimuli with anti-IgE 
and found a more marked basopenia and hypo respon-
siveness to anti-IgE in the autoimmune group. She postu-
lated that this was due to basophil desensitization of the 
FcεRI pathway [57].
Ferrer compared [25] the response of basophils of 
healthy donors, atopic donors and CSU patients to a 
variety of stimuli including anti-IgE, bradykinin, MCP-1, 
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C5a, and serum, and found that the basophils of CSU 
patients exhibited a diminished response to anti-IgE, and 
to a lesser degree to C5a. No difference was observed 
when basophils from CSU patients were incubated with 
bradykinin or MCP-1. These results are not due to a 
variation in histamine content since no significant dif-
ferences was found between the healthy control with the 
urticaria basophils. Although basophils of chronic urti-
caria patients seem to be less responsive to stimuli such 
as anti-IgE or C5a which act through different receptors. 
The abnormality does not seem to be due to a general 
impairment of signaling since CSU basophils do respond 
normally to other stimuli that act independently from the 
IgE receptor such as PAF [58] in addition to bradykinin 
[59], and MCP-1 [60].
Surprisingly, Ferrer also observed [61] prominent hista-
mine release when basophils of CSU patients were stimu-
lated with other sera regardless of source. Thus, marked 
histamine release was obtained with sera derived from 
patients with chronic autoimmune and non autoimmune 
urticaria, or even from the normal control sera. The fac-
tor in serum that stimulates these cells has not been 
identified nor is the abnormal responsiveness of the cells 
understood. But it is clearly specific for CSU since it has 
never found when incubating serum with healthy normal 
or atopic basophil donors.
Basophils derived from patients with non autoimmune 
CSU were just as abnormal as basophils from patients with 
chronic autoimmune urticaria. Both groups of basophil 
were equally responsive to bradykinin, C5a, MCP-1, or 
serum. Both groups were also hyporesponsive to anti IgE, 
thus in vivo desensitization due to the presence of autoan-
tibody does not seem to be the explanation. The abnormal-
ity of signal transduction remains to be defined. Likewise, 
Lourenço [62] also found an increased surface FcεRI 
expression in the basophils of patients suffering from CSU 
and increased response to IL3. However, adding IL3 does 
not change those non releasers sera into releasers [63].
Interestingly, a recent paper by Saini [64] offered 
additional insight into this issue. The authors dem-
onstrated the ability of active CSU serum to transfer 
FcεRI-mediated basophil histamine release suppression 
to healthy basophils. They did so by culturing healthy 
basophils with sera from patients with CSU and found a 
marked suppression of FcεRI-mediated histamine release 
compared with media or media with autologous serum. 
Again, this feature was reversed upon CSU remission. 
Interestingly, it was not overturned by heating serum 
(that would remove IgE), IgG or omalizumab.
Eosinophils
In spite of being the most abundant cells in CSU skin 
biopsies, little attention has been devoted to eosinophils. 
One very interesting paper [65] using a peptide library 
found that CSU patients had IgG against CD23 present 
on the FcεRII. This is a very attractive discovery since 
basophils could become activated through eosinophil 
major basic protein. Unfortunately, no further research 
has been dedicated to this hypothesis.
Th1 or Th2 phenotype
CSU is characterized by a perivascular infiltrate sur-
rounding small venules with a predominance of CD4+ 
T lymphocyte cells [35] along with neutrophils, mast cell 
basophils, and eosinophils. There is also an increase in 
vascular markers both in lesional and in non lesional skin 
[37]. Because of level of inflammatory markers [66, 67], it 
is a systemic inflammatory disease not only confined to 
the skin.
The cellular infiltrate resembles the on which can be 
observed in the late phase allergic reactions. For that 
reason, Ferrer and co-workers questioned [25] whether 
the immunologic profile reflects the predominance of 
a Th1 or Th2 phenotype. They initially approached this 
objective by determining the cytokine profile in the sera 
of patients with chronic urticaria. They measured INFγ 
as a representative of a Th1 profile, and then measured 
IL4 and IL5 as representatives of a Th2 subtype. They 
found that IL4 was higher in the sera of patients with 
chronic urticaria (as well as in atopic subjects) compared 
to controls while IL5 and IFNγ levels were normal. Sig-
nificant differences were found in the ability of CD4+ 
lymphocytes to produce IL4 and INFγ upon PMA-Iono-
mycin stimulus when healthy controls were compared to 
chronic urticaria patients. There was no difference in IL4 
or INFγ production by CD8+  lymphocytes of patients 
vs. the control group. Likewise, no significant differences 
were found when comparing the ratio of INFγ/IL4 pro-
duction by CD4+ or CD8+ lymphocytes of controls and 
urticaria patients. The cytokine profile found in our study 
does not reflect either a Th1 or Th2 predominance.
These data again strengthen an immune basis for 
chronic urticaria, once demonstrated that the CD4+ 
lymphocytes of patients with this disease are activated 
and they release greater amounts of cytokine with a 
non-specific stimulus. On the other hand, this find-
ing is similar to a study in which the cellular infiltrate 
associated with chronic urticaria had a Th0 profile [52]. 
These authors analyzed skin biopsies from chronic urti-
caria patients by in situ hybridization. IL4, IL5 and INF-
gamma revealed higher cytokine m-RNA expression in 
chronic urticaria patients than in healthy controls, with-
out a predominance of either a Th1 or Th2 representative 
cytokine.
In a study composed by eight patients analyzed with 
immunohistochemistry, Kay reported a predominance 
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of Th2 initiating cytokines (IL33, IL25 and TSLP) in skin 
lesions among patients with CSU [68]. However, it should 
be noted that IL33 in some instances could also promote 
a Th1 response [69].
Coagulation pathway
Recently Asero has reported the activation of the extrin-
sic coagulation pathway in patients with CSU suggest-
ing that the coagulation cascade might be involved. It 
was first shown that several markers such as the pro-
thrombin fragment F1+2 [70] and activated factor VII 
[71] were increased. This could be explained because in 
cases of severe CSU, the activation of the coagulation 
cascade could lead to fibrinolysis leading to an increase 
in D-dimer levels [72]. Interestingly, D-dimer levels cor-
relate with the severity and could predict the lack of 
response to antihistamines [73]. However, increased 
D-dimer levelwith disease activity is not specific to 
CSU since it is also seen in bullous pemphigoid [74] and 
hereditary angioedema [75]. Thus, it is not specific for 
mast cell mediated disease.
Moreover, other coagulation cascade proteins are 
able to directly activate mast cells, as it is in the case of 
thrombin that cleaves protease-activated receptors [76] 
1 (PAR-1) and Tissue Factor plus factor VIIa through 
PAR-2 [77].
The real significance of these facts in the pathogen-
esis of CSU is not well understood. However, they could 
amplify the inflammation inducing vascular permeability. 
Furthermore, some cascade proteins are able to induce 
mast cell degranulation (we include a summary of these 
pathways and cell cross-talk in Fig. 1).
Conclusion
Chronic spontaneous urticaria is an inflammatory dis-
ease. There is no single cell type that is uniquely respon-
sible for CSU. Rather, there are several cells involved and 
each has its own unique role. So far, we have been able to 
describe different aspects that point in different direc-
tions but we lack a unified explanation or a chain of facts 
that can explain the final outcome. In this regard, several 
perplexing facts occur. The way corticosteroids are able to 
control an urticaria flare-up without being able to inhibit 
mast cell degranulation, or what is even more surprising, 
the ability of omalizumab to rapidly control the disease by 
means of a mechanism of action which remains elusive.
Fig. 1 We represent in a very simplistic cartoon the possible ways of activation among cells implicated in this disease. Cross-talk between mast cells 
and basophils remain to be defined.
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